Thomas Pezawas1, Robin Ristl2, Christoph Schukro3, Herwig Schmidinger3. 1. Section of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. thomas.pezawas@meduniwien.ac.at. 2. Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. 3. Section of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Abstract
OBJECTIVE: Pulmonary vein isolation (PVI) for paroxysmal or non-paroxysmal atrial fibrillation (AF) should increase health-related quality of life (QOL). DESIGN: Retrospective cohort study of consecutive patients scheduled for PVI. SETTING: University Medical Center. MAIN OUTCOME MEASURES: QOL was assessed using the physical (PCS) and mental (MCS) component summary scores from the SF-12v2 in patients undergoing PVI (mean 50, range 0-100, with higher scores indicating greater QOL). SF-12v2 was obtained at initial presentation (3-months) before PVI and after PVI at the end of follow-up (mean 1.7 ± 1.4 years) which included: (1) Clinical status, ECG, and 24-h ECG every 3 months, (2) trans-telephonic ECGs for 4 weeks every 3 months, or (3) continuous ECG via implanted devices. A recurrence was any atrial arrhythmia >30 s. RESULTS: Out of 229 patients (73% males; 58 ± 11 years), 72% returned SF-12v2 regarding 187 PVI procedures: 56% for 1st PVI, 48% for 2nd PVI, 71% for 3rd PVI, and 44% for 4th PVI. The mean difference between before and after PVI was 10 for PCS and 9 for MCS. History of paroxysmal or non-paroxysmal AF did not influence QOL (p = 0.724). Patients with an estimated PCS improvement ≥ 10 or an estimated MCS improvement ≥ 9 had the best outcome after repeated PVI. Success rates were 72 or 82% after 1 year compared to 20 and 22% in patients not achieving this improvement, respectively (p < 0.0001). CONCLUSION: Improvement in QOL correlates with success of AF ablation after single and repeated PVI. Assessment of QOL pre- and post-PVI can complement ECG techniques for PVI success monitoring.
OBJECTIVE: Pulmonary vein isolation (PVI) for paroxysmal or non-paroxysmal atrial fibrillation (AF) should increase health-related quality of life (QOL). DESIGN: Retrospective cohort study of consecutive patients scheduled for PVI. SETTING: University Medical Center. MAIN OUTCOME MEASURES: QOL was assessed using the physical (PCS) and mental (MCS) component summary scores from the SF-12v2 in patients undergoing PVI (mean 50, range 0-100, with higher scores indicating greater QOL). SF-12v2 was obtained at initial presentation (3-months) before PVI and after PVI at the end of follow-up (mean 1.7 ± 1.4 years) which included: (1) Clinical status, ECG, and 24-h ECG every 3 months, (2) trans-telephonic ECGs for 4 weeks every 3 months, or (3) continuous ECG via implanted devices. A recurrence was any atrial arrhythmia >30 s. RESULTS: Out of 229 patients (73% males; 58 ± 11 years), 72% returned SF-12v2 regarding 187 PVI procedures: 56% for 1st PVI, 48% for 2nd PVI, 71% for 3rd PVI, and 44% for 4th PVI. The mean difference between before and after PVI was 10 for PCS and 9 for MCS. History of paroxysmal or non-paroxysmal AF did not influence QOL (p = 0.724). Patients with an estimated PCS improvement ≥ 10 or an estimated MCS improvement ≥ 9 had the best outcome after repeated PVI. Success rates were 72 or 82% after 1 year compared to 20 and 22% in patients not achieving this improvement, respectively (p < 0.0001). CONCLUSION: Improvement in QOL correlates with success of AF ablation after single and repeated PVI. Assessment of QOL pre- and post-PVI can complement ECG techniques for PVI success monitoring.
Entities:
Keywords:
Ablation; Atrial fibrillation; Pulmonary vein isolation; Quality of life; Rhythm control
Authors: P Dorian; W Jung; D Newman; M Paquette; K Wood; G M Ayers; J Camm; M Akhtar; B Luderitz Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: Daniel Steven; Boris Hoffmann; Thomas Rostock; Imke Drewitz; Arian Sultan; Helge Servatius; Jakob Lüker; Kai Müllerleile; Stephan Willems Journal: Clin Res Cardiol Suppl Date: 2011-05
Authors: Anita Wokhlu; Kristi H Monahan; David O Hodge; Samuel J Asirvatham; Paul A Friedman; Thomas M Munger; David J Bradley; Christine M Bluhm; Janis M Haroldson; Douglas L Packer Journal: J Am Coll Cardiol Date: 2010-05-25 Impact factor: 24.094
Authors: Louise S Jenkins; Michael Brodsky; Eleanor Schron; Mina Chung; Thomas Rocco; Ellis Lader; Martha Constantine; Robert Sheppard; Donald Holmes; Donna Mateski; Liz Floden; Marilyn Prasun; H Leon Greene; Lynn Shemanski Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: Thomas Pezawas; Robin Ristl; Mariusz Bilinski; Christoph Schukro; Herwig Schmidinger Journal: Int J Cardiol Date: 2014-03-15 Impact factor: 4.164
Authors: Thomas Pezawas; Thomas Binder; Robin Ristl; Barbara Schneider; Stefan Stojkovic; Christoph Schukro; Herwig Schmidinger Journal: J Cardiol Date: 2014-08-26 Impact factor: 3.159